{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"ss-31-gut","title":"SS-31 (Elamipretide) Mitochondrial Support for Gut: Evidence Review","body":"## What's breaking down\n\nGut barrier integrity depends on intestinal epithelial cells maintaining tight junctions and low oxidative stress. Mitochondrial dysfunction in these cells can increase reactive oxygen species, disrupt cardiolipin in the inner membrane, impair ATP production, and trigger apoptosis. This process weakens tight junction proteins such as ZO-1 and occludin. The result is higher paracellular permeability. Repair pathways that stabilize mitochondria can address the root layer rather than only downstream inflammation or symptoms.\n\n## Why SS-31 (Elamipretide) might help you\n\nIf mitochondrial oxidative stress and cardiolipin instability form part of your gut barrier challenge, SS-31 (Elamipretide) is discussed because it binds cardiolipin directly. Step one: the peptide accumulates in the inner mitochondrial membrane. Step two: it stabilizes cristae structure and supports electron transport chain efficiency. Step three: this reduces electron leak and ROS production while preserving ATP output. Step four: lower ROS can limit apoptosis and support maintenance of tight junction proteins. Therefore for you: If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\n\n## How these fit together\n\nSingle-compound focus. SS-31 (Elamipretide) maps to the mitochondrial layer of intestinal epithelial cell health. No sibling peptides are in scope for this review.\n\n## What the evidence actually shows\n\nHuman data specific to gut: none identified. Preclinical data: one in-vitro study examined mycophenolic acid (MPA)-induced damage in intestinal epithelial cells. MPA increased ROS, reduced tight junction expression, and raised apoptosis. SS-31 treatment lowered intracellular and intramitochondrial ROS, upregulated tight junction proteins, and reduced apoptosis rates (preclinical tier, Deng et al. 2022, PMC9277164). Multiple rodent LPS models (LPS models systemic inflammation often linked to gut-derived endotoxins) showed SS-31 preserved mitochondrial membrane potential, reduced hippocampal oxidative stress, and improved behavioral outcomes, but these did not measure intestinal barrier endpoints directly (preclinical tier, Zhao et al. 2019). Broader mitochondrial studies in kidney and heart models confirm cardiolipin stabilization and ROS reduction in animal tissue (preclinical tier). No randomized human trials report gut permeability, microbiome, or intestinal histology outcomes.\n\n## What scientists say\n\nResearchers describe SS-31 as a cardiolipin-targeting tetrapeptide that improves bioenergetics without acting as a general antioxidant. Reviews note consistent mitochondrial protection across cell types in culture and rodents, with emphasis on cristae preservation and reduced cytochrome c release. Clinical development has focused on primary mitochondrial myopathy, heart failure, and Barth syndrome; gut-specific applications remain exploratory (mechanistic tier, multiple reviews 2024-2025).\n\n## What people say on Reddit\n\nAnecdotal reports in CFS and ME/CFS communities mention SS-31 primarily for energy and cognitive function. Some users note transient GI symptoms (nausea, diarrhea, hot flashes) during initial dosing that later resolved; others report no gut-specific benefits or changes. One user described fixing digestion first with other interventions before adding SS-31 for mitochondrial support (anecdotal tier, r/cfs threads 2025).\n\n## What people say on X\n\nLimited public discussion. Posts focus on mitochondrial medicine in general or Barth syndrome approval rather than gut outcomes. No widespread user reports tie SS-31 directly to intestinal barrier improvements (anecdotal tier).\n\n## What we do not know\n\nNo human pharmacokinetic or efficacy data exist for intestinal epithelial mitochondria or gut permeability. Duration of effect on tight junctions, interactions with microbiome composition, and long-term outcomes in chronic gut conditions remain unstudied in controlled settings. Dose-response relationships specific to gut tissue are unknown.\n\n## Safety and limits\n\nHuman trials in non-gut indications report good short-term tolerability with injection-site reactions as the main observation. Some preclinical and anecdotal sources note possible transient GI distress. Long-term human safety beyond trial durations is not established. Evidence for gut applications rests entirely on mechanistic and limited preclinical layers.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/ss-31-gut/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"SS-31 binds cardiolipin in the inner mitochondrial membrane and stabilizes cristae structure.","section":"Why SS-31 (Elamipretide) might help you","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Core mechanism explaining potential intestinal epithelial support","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"In an in-vitro model, SS-31 reduced MPA-induced ROS, upregulated tight junction proteins, and lowered apoptosis in intestinal epithelial cells.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Only direct gut-related preclinical finding identified","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No human trials report effects of SS-31 on gut barrier function, permeability, or intestinal histology.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Clarifies absence of clinical gut data","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"LPS rodent models show SS-31 preserves mitochondrial function under inflammatory stress, though gut barrier endpoints were not measured.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s4"],"source_status":"sourced","why_material":"Supports mitochondrial layer relevance via LPS (gut-derived endotoxin model)","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://www.mdpi.com/1422-0067/26/3/944","title":"Elamipretide: A Review of Its Structure, Mechanism, and Therapeutic Potential","quote":"Elamipretide (SS-31, MTP-131, Bendavia) is a mitochondria-targeting tetrapeptide designed to treat mitochondrial dysfunction via binding to cardiolipin (CL) on the inner mitochondrial membrane","summary":"Details cardiolipin binding and mitochondrial stabilization mechanism","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:54:00.910Z","link_status":"http_403","quote_status":"unverified","prev":"genesis","hash":"559041091a565c5a1326b3feb65f43b495c38a3bb8e21c8be89d3f7d08cb7477"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9277164/","title":"Mycophenolic Acid Induces the Intestinal Epithelial Barrier Dysfunction","quote":"These results suggest that SS-31 protects the intestinal mechanical barrier and reduces apoptosis in vitro by inhibiting MPA-induced oxidative stress.","summary":"Direct preclinical evidence on intestinal epithelial cells","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:54:00.910Z","link_status":"ok","quote_status":"unverified","prev":"559041091a565c5a1326b3feb65f43b495c38a3bb8e21c8be89d3f7d08cb7477","hash":"93038c94e49bff6636d9a516159872cebe3024903422a61dba629ca8fd8da66d"},{"id":"s3","type":"review","url":"https://www.innerbody.com/ss-31-peptide","title":"SS-31 Peptide | Benefits, Safety & Buying Advice [2026]","quote":"Human trials focus on mitochondrial myopathy, heart failure, and renal artery stenosis; no gut-specific outcomes reported.","summary":"Confirms lack of human gut data across clinical development","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:54:00.910Z","link_status":"ok","quote_status":"unverified","prev":"93038c94e49bff6636d9a516159872cebe3024903422a61dba629ca8fd8da66d","hash":"7a4c2cf83e1cbdcbcea3ba4095c6e04330263f1635b46a2681c1b1adab14e768"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31747905/","title":"Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice","quote":"Treatment with elamipretide significantly ameliorated LPS-induced learning and memory impairment","summary":"LPS model with mitochondrial endpoints","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:54:00.910Z","link_status":"ok","quote_status":"verified","prev":"7a4c2cf83e1cbdcbcea3ba4095c6e04330263f1635b46a2681c1b1adab14e768","hash":"4c0cbe43ff1d7832cfa67ae3bf975c41d4b4477753647937d3cacee71c9e3488"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:54:01.705Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"SS-31 (Elamipretide) Mitochondrial Support for Gut: Evidence Review","register":"source_ledger","body":"## What's breaking down\n\nGut barrier integrity depends on intestinal epithelial cells maintaining tight junctions and low oxidative stress. Mitochondrial dysfunction in these cells can increase reactive oxygen species, disrupt cardiolipin in the inner membrane, impair ATP production, and trigger apoptosis. This process weakens tight junction proteins such as ZO-1 and occludin. The result is higher paracellular permeability. Repair pathways that stabilize mitochondria can address the root layer rather than only downstream inflammation or symptoms.\n\n## Why SS-31 (Elamipretide) might help you\n\nIf mitochondrial oxidative stress and cardiolipin instability form part of your gut barrier challenge, SS-31 (Elamipretide) is discussed because it binds cardiolipin directly. Step one: the peptide accumulates in the inner mitochondrial membrane. Step two: it stabilizes cristae structure and supports electron transport chain efficiency. Step three: this reduces electron leak and ROS production while preserving ATP output. Step four: lower ROS can limit apoptosis and support maintenance of tight junction proteins. Therefore for you: If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\n\n## How these fit together\n\nSingle-compound focus. SS-31 (Elamipretide) maps to the mitochondrial layer of intestinal epithelial cell health. No sibling peptides are in scope for this review.\n\n## What the evidence actually shows\n\nHuman data specific to gut: none identified. Preclinical data: one in-vitro study examined mycophenolic acid (MPA)-induced damage in intestinal epithelial cells. MPA increased ROS, reduced tight junction expression, and raised apoptosis. SS-31 treatment lowered intracellular and intramitochondrial ROS, upregulated tight junction proteins, and reduced apoptosis rates (preclinical tier, Deng et al. 2022, PMC9277164). Multiple rodent LPS models (LPS models systemic inflammation often linked to gut-derived endotoxins) showed SS-31 preserved mitochondrial membrane potential, reduced hippocampal oxidative stress, and improved behavioral outcomes, but these did not measure intestinal barrier endpoints directly (preclinical tier, Zhao et al. 2019). Broader mitochondrial studies in kidney and heart models confirm cardiolipin stabilization and ROS reduction in animal tissue (preclinical tier). No randomized human trials report gut permeability, microbiome, or intestinal histology outcomes.\n\n## What scientists say\n\nResearchers describe SS-31 as a cardiolipin-targeting tetrapeptide that improves bioenergetics without acting as a general antioxidant. Reviews note consistent mitochondrial protection across cell types in culture and rodents, with emphasis on cristae preservation and reduced cytochrome c release. Clinical development has focused on primary mitochondrial myopathy, heart failure, and Barth syndrome; gut-specific applications remain exploratory (mechanistic tier, multiple reviews 2024-2025).\n\n## What people say on Reddit\n\nAnecdotal reports in CFS and ME/CFS communities mention SS-31 primarily for energy and cognitive function. Some users note transient GI symptoms (nausea, diarrhea, hot flashes) during initial dosing that later resolved; others report no gut-specific benefits or changes. One user described fixing digestion first with other interventions before adding SS-31 for mitochondrial support (anecdotal tier, r/cfs threads 2025).\n\n## What people say on X\n\nLimited public discussion. Posts focus on mitochondrial medicine in general or Barth syndrome approval rather than gut outcomes. No widespread user reports tie SS-31 directly to intestinal barrier improvements (anecdotal tier).\n\n## What we do not know\n\nNo human pharmacokinetic or efficacy data exist for intestinal epithelial mitochondria or gut permeability. Duration of effect on tight junctions, interactions with microbiome composition, and long-term outcomes in chronic gut conditions remain unstudied in controlled settings. Dose-response relationships specific to gut tissue are unknown.\n\n## Safety and limits\n\nHuman trials in non-gut indications report good short-term tolerability with injection-site reactions as the main observation. Some preclinical and anecdotal sources note possible transient GI distress. Long-term human safety beyond trial durations is not established. Evidence for gut applications rests entirely on mechanistic and limited preclinical layers.","claims":[{"id":"c1","text":"SS-31 binds cardiolipin in the inner mitochondrial membrane and stabilizes cristae structure.","section":"Why SS-31 (Elamipretide) might help you","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Core mechanism explaining potential intestinal epithelial support","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"In an in-vitro model, SS-31 reduced MPA-induced ROS, upregulated tight junction proteins, and lowered apoptosis in intestinal epithelial cells.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Only direct gut-related preclinical finding identified","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No human trials report effects of SS-31 on gut barrier function, permeability, or intestinal histology.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Clarifies absence of clinical gut data","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"LPS rodent models show SS-31 preserves mitochondrial function under inflammatory stress, though gut barrier endpoints were not measured.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s4"],"source_status":"sourced","why_material":"Supports mitochondrial layer relevance via LPS (gut-derived endotoxin model)","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://www.mdpi.com/1422-0067/26/3/944","title":"Elamipretide: A Review of Its Structure, Mechanism, and Therapeutic Potential","quote":"Elamipretide (SS-31, MTP-131, Bendavia) is a mitochondria-targeting tetrapeptide designed to treat mitochondrial dysfunction via binding to cardiolipin (CL) on the inner mitochondrial membrane","link_status":"http_403","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9277164/","title":"Mycophenolic Acid Induces the Intestinal Epithelial Barrier Dysfunction","quote":"These results suggest that SS-31 protects the intestinal mechanical barrier and reduces apoptosis in vitro by inhibiting MPA-induced oxidative stress.","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"review","url":"https://www.innerbody.com/ss-31-peptide","title":"SS-31 Peptide | Benefits, Safety & Buying Advice [2026]","quote":"Human trials focus on mitochondrial myopathy, heart failure, and renal artery stenosis; no gut-specific outcomes reported.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31747905/","title":"Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice","quote":"Treatment with elamipretide significantly ameliorated LPS-induced learning and memory impairment","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":36102,"tokens_out":2788,"cost":0.0520975,"prev_hash":"genesis","hash":"477ff55f9f6d0b3c8c8382d42e046a19f441e73c6f756acd9f459e0d6d360c3c"}],"provenance":[{"ts":"2026-06-29T23:54:01.705Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Ss 31 for Gut\nSlug: ss-31-gut\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\",\"section_title\":\"Why SS-31 (Elamipretide) might help you\",\"layer\":\"mitochondrial\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **SS-31 (Elamipretide)** → mitochondrial\",\"section_headings\":[\"What's breaking down\",\"Why SS-31 (Elamipretide) might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one","response":"{\n  \"slug\": \"ss-31-gut\",\n  \"title\": \"SS-31 (Elamipretide) Mitochondrial Support for Gut: Evidence Review\",\n  \"body\": \"## What's breaking down\\n\\nGut barrier integrity depends on intestinal epithelial cells maintaining tight junctions and low oxidative stress. Mitochondrial dysfunction in these cells can increase reactive oxygen species, disrupt cardiolipin in the inner membrane, impair ATP production, and trigger apoptosis. This process weakens tight junction proteins such as ZO-1 and occludin. The result is higher paracellular permeability. Repair pathways that stabilize mitochondria can address the root layer rather than only downstream inflammation or symptoms.\\n\\n## Why SS-31 (Elamipretide) might help you\\n\\nIf mitochondrial oxidative stress and cardiolipin instability form part of your gut barrier challenge, SS-31 (Elamipretide) is discussed because it binds cardiolipin directly. Step one: the peptide accumulates in the inner mitochondrial membrane. Step two: it stabilizes cristae structure and supports electron transport chain efficiency. Step three: this reduces electron leak and ROS production while preserving ATP output. Step four: lower ROS can limit apoptosis and support maintenance of tight junction proteins. Therefore for you: If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\\n\\n## How these fit together\\n\\nSingle-compound focus. SS-31 (Elamipretide) maps to the mitochondrial layer of intestinal epithelial cell health. No sibling peptides are in scope for this review.\\n\\n## What the evidence actually shows\\n\\nHuman data specific to gut: none identified. Preclinical data: one in-vitro study examined mycophenolic acid (MPA)-induced damage in intestinal epithelial cells. MPA increased ROS, reduced tight junction expression, and raised apoptosis. SS-31 treatment lowered intracellular and intramitochondrial ROS, upregulated tight junction proteins, and reduced apoptosis ra","tokens_in":36102,"tokens_out":2788,"cost":0,"prev":"genesis","hash":"9ef6e05d33e4b0035faecc25cfe34a78a14f1fbd6440ea0bc01c0cf919820f42"},{"ts":"2026-07-17T02:42:04.241Z","model":"owner","action":"voxel_divide","prompt":"","input":"ss-31-gut","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9ef6e05d33e4b0035faecc25cfe34a78a14f1fbd6440ea0bc01c0cf919820f42","hash":"95964720ddc6a7bcf6cc236e2280ce22121375af87b3c89b96887feb44d986fb"}],"energy":{"passes":2,"tokens_in":36102,"tokens_out":2788,"tokens_total":38890,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"95964720ddc6a7bcf6cc236e2280ce22121375af87b3c89b96887feb44d986fb"},"posted_at":"2026-06-29T21:33:22.623Z","created_at":"2026-06-29T21:33:22.623Z","updated_at":"2026-07-17T02:42:04.241Z","machine":{"shape":"article.machine/v1","slug":"ss-31-gut","kind":"article","read":{"human":"https://miscsubjects.com/a/ss-31-gut","json":"https://miscsubjects.com/api/articles/ss-31-gut","bundle":"https://miscsubjects.com/api/articles/ss-31-gut/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/ss-31-gut/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=ss-31-gut","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-gut\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-gut\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/ss-31-gut/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"ss-31-gut\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/ss-31-gut | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/ss-31-gut","json":"/api/articles/ss-31-gut","markdown":"/api/articles/ss-31-gut/bundle?format=markdown","skill":"/api/articles/ss-31-gut/skill","topology":"/api/articles/ss-31-gut/topology","versions":"/api/articles/ss-31-gut/revisions","invocations":"/api/articles/ss-31-gut/invocations"},"editorial_review":null,"editorial_audit":{"slug":"ss-31-gut","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"cb54f4766e31026da32daf881b3666965ee597d835c84d97a6dd20d6cdb696a8","object":{"object_type":"article-object","identity":{"id":"article:ss-31-gut","slug":"ss-31-gut","title":"SS-31 (Elamipretide) Mitochondrial Support for Gut: Evidence Review"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/ss-31-gut","role":"explain","audience":"human"},"skill":{"route":"/api/articles/ss-31-gut/skill","role":"direct behavior","audience":"model","content":"---\nname: ss-31-gut\ndescription: Apply the SS-31 (Elamipretide) Mitochondrial Support for Gut: Evidence Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# SS-31 (Elamipretide) Mitochondrial Support for Gut: Evidence Review\n\nThis Skill is the behavioral expression of [the canonical article](/a/ss-31-gut). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/ss-31-gut.\n- Read claims and relationships at /api/articles/ss-31-gut/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Gut barrier integrity depends on intestinal epithelial cells maintaining tight junctions and low oxidative stress. Mitochondrial dysfunction in these cells can increase reactive oxygen species, disrupt cardiolipin in th\n\n## Representations\n\n- Human: /a/ss-31-gut\n- JSON: /api/articles/ss-31-gut\n- Relationships: /api/articles/ss-31-gut/topology\n- History: /api/articles/ss-31-gut/revisions\n"},"json":{"route":"/api/articles/ss-31-gut","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/ss-31-gut/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","ss","31","gut"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/ss-31-gut/invocations?status=success","failure_events":"/api/articles/ss-31-gut/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"ss-31-gut","title":"SS-31 (Elamipretide) Mitochondrial Support for Gut: Evidence Review","body":"## What's breaking down\n\nGut barrier integrity depends on intestinal epithelial cells maintaining tight junctions and low oxidative stress. Mitochondrial dysfunction in these cells can increase reactive oxygen species, disrupt cardiolipin in the inner membrane, impair ATP production, and trigger apoptosis. This process weakens tight junction proteins such as ZO-1 and occludin. The result is higher paracellular permeability. Repair pathways that stabilize mitochondria can address the root layer rather than only downstream inflammation or symptoms.\n\n## Why SS-31 (Elamipretide) might help you\n\nIf mitochondrial oxidative stress and cardiolipin instability form part of your gut barrier challenge, SS-31 (Elamipretide) is discussed because it binds cardiolipin directly. Step one: the peptide accumulates in the inner mitochondrial membrane. Step two: it stabilizes cristae structure and supports electron transport chain efficiency. Step three: this reduces electron leak and ROS production while preserving ATP output. Step four: lower ROS can limit apoptosis and support maintenance of tight junction proteins. Therefore for you: If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\n\n## How these fit together\n\nSingle-compound focus. SS-31 (Elamipretide) maps to the mitochondrial layer of intestinal epithelial cell health. No sibling peptides are in scope for this review.\n\n## What the evidence actually shows\n\nHuman data specific to gut: none identified. Preclinical data: one in-vitro study examined mycophenolic acid (MPA)-induced damage in intestinal epithelial cells. MPA increased ROS, reduced tight junction expression, and raised apoptosis. SS-31 treatment lowered intracellular and intramitochondrial ROS, upregulated tight junction proteins, and reduced apoptosis rates (preclinical tier, Deng et al. 2022, PMC9277164). Multiple rodent LPS models (LPS models systemic inflammation often linked to gut-derived endotoxins) showed SS-31 preserved mitochondrial membrane potential, reduced hippocampal oxidative stress, and improved behavioral outcomes, but these did not measure intestinal barrier endpoints directly (preclinical tier, Zhao et al. 2019). Broader mitochondrial studies in kidney and heart models confirm cardiolipin stabilization and ROS reduction in animal tissue (preclinical tier). No randomized human trials report gut permeability, microbiome, or intestinal histology outcomes.\n\n## What scientists say\n\nResearchers describe SS-31 as a cardiolipin-targeting tetrapeptide that improves bioenergetics without acting as a general antioxidant. Reviews note consistent mitochondrial protection across cell types in culture and rodents, with emphasis on cristae preservation and reduced cytochrome c release. Clinical development has focused on primary mitochondrial myopathy, heart failure, and Barth syndrome; gut-specific applications remain exploratory (mechanistic tier, multiple reviews 2024-2025).\n\n## What people say on Reddit\n\nAnecdotal reports in CFS and ME/CFS communities mention SS-31 primarily for energy and cognitive function. Some users note transient GI symptoms (nausea, diarrhea, hot flashes) during initial dosing that later resolved; others report no gut-specific benefits or changes. One user described fixing digestion first with other interventions before adding SS-31 for mitochondrial support (anecdotal tier, r/cfs threads 2025).\n\n## What people say on X\n\nLimited public discussion. Posts focus on mitochondrial medicine in general or Barth syndrome approval rather than gut outcomes. No widespread user reports tie SS-31 directly to intestinal barrier improvements (anecdotal tier).\n\n## What we do not know\n\nNo human pharmacokinetic or efficacy data exist for intestinal epithelial mitochondria or gut permeability. Duration of effect on tight junctions, interactions with microbiome composition, and long-term outcomes in chronic gut conditions remain unstudied in controlled settings. Dose-response relationships specific to gut tissue are unknown.\n\n## Safety and limits\n\nHuman trials in non-gut indications report good short-term tolerability with injection-site reactions as the main observation. Some preclinical and anecdotal sources note possible transient GI distress. Long-term human safety beyond trial durations is not established. Evidence for gut applications rests entirely on mechanistic and limited preclinical layers.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/ss-31-gut/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"SS-31 binds cardiolipin in the inner mitochondrial membrane and stabilizes cristae structure.","section":"Why SS-31 (Elamipretide) might help you","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Core mechanism explaining potential intestinal epithelial support","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"In an in-vitro model, SS-31 reduced MPA-induced ROS, upregulated tight junction proteins, and lowered apoptosis in intestinal epithelial cells.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Only direct gut-related preclinical finding identified","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No human trials report effects of SS-31 on gut barrier function, permeability, or intestinal histology.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Clarifies absence of clinical gut data","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"LPS rodent models show SS-31 preserves mitochondrial function under inflammatory stress, though gut barrier endpoints were not measured.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s4"],"source_status":"sourced","why_material":"Supports mitochondrial layer relevance via LPS (gut-derived endotoxin model)","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://www.mdpi.com/1422-0067/26/3/944","title":"Elamipretide: A Review of Its Structure, Mechanism, and Therapeutic Potential","quote":"Elamipretide (SS-31, MTP-131, Bendavia) is a mitochondria-targeting tetrapeptide designed to treat mitochondrial dysfunction via binding to cardiolipin (CL) on the inner mitochondrial membrane","summary":"Details cardiolipin binding and mitochondrial stabilization mechanism","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:54:00.910Z","link_status":"http_403","quote_status":"unverified","prev":"genesis","hash":"559041091a565c5a1326b3feb65f43b495c38a3bb8e21c8be89d3f7d08cb7477"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9277164/","title":"Mycophenolic Acid Induces the Intestinal Epithelial Barrier Dysfunction","quote":"These results suggest that SS-31 protects the intestinal mechanical barrier and reduces apoptosis in vitro by inhibiting MPA-induced oxidative stress.","summary":"Direct preclinical evidence on intestinal epithelial cells","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:54:00.910Z","link_status":"ok","quote_status":"unverified","prev":"559041091a565c5a1326b3feb65f43b495c38a3bb8e21c8be89d3f7d08cb7477","hash":"93038c94e49bff6636d9a516159872cebe3024903422a61dba629ca8fd8da66d"},{"id":"s3","type":"review","url":"https://www.innerbody.com/ss-31-peptide","title":"SS-31 Peptide | Benefits, Safety & Buying Advice [2026]","quote":"Human trials focus on mitochondrial myopathy, heart failure, and renal artery stenosis; no gut-specific outcomes reported.","summary":"Confirms lack of human gut data across clinical development","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:54:00.910Z","link_status":"ok","quote_status":"unverified","prev":"93038c94e49bff6636d9a516159872cebe3024903422a61dba629ca8fd8da66d","hash":"7a4c2cf83e1cbdcbcea3ba4095c6e04330263f1635b46a2681c1b1adab14e768"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31747905/","title":"Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice","quote":"Treatment with elamipretide significantly ameliorated LPS-induced learning and memory impairment","summary":"LPS model with mitochondrial endpoints","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:54:00.910Z","link_status":"ok","quote_status":"verified","prev":"7a4c2cf83e1cbdcbcea3ba4095c6e04330263f1635b46a2681c1b1adab14e768","hash":"4c0cbe43ff1d7832cfa67ae3bf975c41d4b4477753647937d3cacee71c9e3488"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:54:01.705Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"SS-31 (Elamipretide) Mitochondrial Support for Gut: Evidence Review","register":"source_ledger","body":"## What's breaking down\n\nGut barrier integrity depends on intestinal epithelial cells maintaining tight junctions and low oxidative stress. Mitochondrial dysfunction in these cells can increase reactive oxygen species, disrupt cardiolipin in the inner membrane, impair ATP production, and trigger apoptosis. This process weakens tight junction proteins such as ZO-1 and occludin. The result is higher paracellular permeability. Repair pathways that stabilize mitochondria can address the root layer rather than only downstream inflammation or symptoms.\n\n## Why SS-31 (Elamipretide) might help you\n\nIf mitochondrial oxidative stress and cardiolipin instability form part of your gut barrier challenge, SS-31 (Elamipretide) is discussed because it binds cardiolipin directly. Step one: the peptide accumulates in the inner mitochondrial membrane. Step two: it stabilizes cristae structure and supports electron transport chain efficiency. Step three: this reduces electron leak and ROS production while preserving ATP output. Step four: lower ROS can limit apoptosis and support maintenance of tight junction proteins. Therefore for you: If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\n\n## How these fit together\n\nSingle-compound focus. SS-31 (Elamipretide) maps to the mitochondrial layer of intestinal epithelial cell health. No sibling peptides are in scope for this review.\n\n## What the evidence actually shows\n\nHuman data specific to gut: none identified. Preclinical data: one in-vitro study examined mycophenolic acid (MPA)-induced damage in intestinal epithelial cells. MPA increased ROS, reduced tight junction expression, and raised apoptosis. SS-31 treatment lowered intracellular and intramitochondrial ROS, upregulated tight junction proteins, and reduced apoptosis rates (preclinical tier, Deng et al. 2022, PMC9277164). Multiple rodent LPS models (LPS models systemic inflammation often linked to gut-derived endotoxins) showed SS-31 preserved mitochondrial membrane potential, reduced hippocampal oxidative stress, and improved behavioral outcomes, but these did not measure intestinal barrier endpoints directly (preclinical tier, Zhao et al. 2019). Broader mitochondrial studies in kidney and heart models confirm cardiolipin stabilization and ROS reduction in animal tissue (preclinical tier). No randomized human trials report gut permeability, microbiome, or intestinal histology outcomes.\n\n## What scientists say\n\nResearchers describe SS-31 as a cardiolipin-targeting tetrapeptide that improves bioenergetics without acting as a general antioxidant. Reviews note consistent mitochondrial protection across cell types in culture and rodents, with emphasis on cristae preservation and reduced cytochrome c release. Clinical development has focused on primary mitochondrial myopathy, heart failure, and Barth syndrome; gut-specific applications remain exploratory (mechanistic tier, multiple reviews 2024-2025).\n\n## What people say on Reddit\n\nAnecdotal reports in CFS and ME/CFS communities mention SS-31 primarily for energy and cognitive function. Some users note transient GI symptoms (nausea, diarrhea, hot flashes) during initial dosing that later resolved; others report no gut-specific benefits or changes. One user described fixing digestion first with other interventions before adding SS-31 for mitochondrial support (anecdotal tier, r/cfs threads 2025).\n\n## What people say on X\n\nLimited public discussion. Posts focus on mitochondrial medicine in general or Barth syndrome approval rather than gut outcomes. No widespread user reports tie SS-31 directly to intestinal barrier improvements (anecdotal tier).\n\n## What we do not know\n\nNo human pharmacokinetic or efficacy data exist for intestinal epithelial mitochondria or gut permeability. Duration of effect on tight junctions, interactions with microbiome composition, and long-term outcomes in chronic gut conditions remain unstudied in controlled settings. Dose-response relationships specific to gut tissue are unknown.\n\n## Safety and limits\n\nHuman trials in non-gut indications report good short-term tolerability with injection-site reactions as the main observation. Some preclinical and anecdotal sources note possible transient GI distress. Long-term human safety beyond trial durations is not established. Evidence for gut applications rests entirely on mechanistic and limited preclinical layers.","claims":[{"id":"c1","text":"SS-31 binds cardiolipin in the inner mitochondrial membrane and stabilizes cristae structure.","section":"Why SS-31 (Elamipretide) might help you","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Core mechanism explaining potential intestinal epithelial support","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"In an in-vitro model, SS-31 reduced MPA-induced ROS, upregulated tight junction proteins, and lowered apoptosis in intestinal epithelial cells.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Only direct gut-related preclinical finding identified","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No human trials report effects of SS-31 on gut barrier function, permeability, or intestinal histology.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Clarifies absence of clinical gut data","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"LPS rodent models show SS-31 preserves mitochondrial function under inflammatory stress, though gut barrier endpoints were not measured.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s4"],"source_status":"sourced","why_material":"Supports mitochondrial layer relevance via LPS (gut-derived endotoxin model)","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://www.mdpi.com/1422-0067/26/3/944","title":"Elamipretide: A Review of Its Structure, Mechanism, and Therapeutic Potential","quote":"Elamipretide (SS-31, MTP-131, Bendavia) is a mitochondria-targeting tetrapeptide designed to treat mitochondrial dysfunction via binding to cardiolipin (CL) on the inner mitochondrial membrane","link_status":"http_403","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9277164/","title":"Mycophenolic Acid Induces the Intestinal Epithelial Barrier Dysfunction","quote":"These results suggest that SS-31 protects the intestinal mechanical barrier and reduces apoptosis in vitro by inhibiting MPA-induced oxidative stress.","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"review","url":"https://www.innerbody.com/ss-31-peptide","title":"SS-31 Peptide | Benefits, Safety & Buying Advice [2026]","quote":"Human trials focus on mitochondrial myopathy, heart failure, and renal artery stenosis; no gut-specific outcomes reported.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31747905/","title":"Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice","quote":"Treatment with elamipretide significantly ameliorated LPS-induced learning and memory impairment","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":36102,"tokens_out":2788,"cost":0.0520975,"prev_hash":"genesis","hash":"477ff55f9f6d0b3c8c8382d42e046a19f441e73c6f756acd9f459e0d6d360c3c"}],"provenance":[{"ts":"2026-06-29T23:54:01.705Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Ss 31 for Gut\nSlug: ss-31-gut\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\",\"section_title\":\"Why SS-31 (Elamipretide) might help you\",\"layer\":\"mitochondrial\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **SS-31 (Elamipretide)** → mitochondrial\",\"section_headings\":[\"What's breaking down\",\"Why SS-31 (Elamipretide) might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one","response":"{\n  \"slug\": \"ss-31-gut\",\n  \"title\": \"SS-31 (Elamipretide) Mitochondrial Support for Gut: Evidence Review\",\n  \"body\": \"## What's breaking down\\n\\nGut barrier integrity depends on intestinal epithelial cells maintaining tight junctions and low oxidative stress. Mitochondrial dysfunction in these cells can increase reactive oxygen species, disrupt cardiolipin in the inner membrane, impair ATP production, and trigger apoptosis. This process weakens tight junction proteins such as ZO-1 and occludin. The result is higher paracellular permeability. Repair pathways that stabilize mitochondria can address the root layer rather than only downstream inflammation or symptoms.\\n\\n## Why SS-31 (Elamipretide) might help you\\n\\nIf mitochondrial oxidative stress and cardiolipin instability form part of your gut barrier challenge, SS-31 (Elamipretide) is discussed because it binds cardiolipin directly. Step one: the peptide accumulates in the inner mitochondrial membrane. Step two: it stabilizes cristae structure and supports electron transport chain efficiency. Step three: this reduces electron leak and ROS production while preserving ATP output. Step four: lower ROS can limit apoptosis and support maintenance of tight junction proteins. Therefore for you: If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\\n\\n## How these fit together\\n\\nSingle-compound focus. SS-31 (Elamipretide) maps to the mitochondrial layer of intestinal epithelial cell health. No sibling peptides are in scope for this review.\\n\\n## What the evidence actually shows\\n\\nHuman data specific to gut: none identified. Preclinical data: one in-vitro study examined mycophenolic acid (MPA)-induced damage in intestinal epithelial cells. MPA increased ROS, reduced tight junction expression, and raised apoptosis. SS-31 treatment lowered intracellular and intramitochondrial ROS, upregulated tight junction proteins, and reduced apoptosis ra","tokens_in":36102,"tokens_out":2788,"cost":0,"prev":"genesis","hash":"9ef6e05d33e4b0035faecc25cfe34a78a14f1fbd6440ea0bc01c0cf919820f42"},{"ts":"2026-07-17T02:42:04.241Z","model":"owner","action":"voxel_divide","prompt":"","input":"ss-31-gut","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9ef6e05d33e4b0035faecc25cfe34a78a14f1fbd6440ea0bc01c0cf919820f42","hash":"95964720ddc6a7bcf6cc236e2280ce22121375af87b3c89b96887feb44d986fb"}],"energy":{"passes":2,"tokens_in":36102,"tokens_out":2788,"tokens_total":38890,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"95964720ddc6a7bcf6cc236e2280ce22121375af87b3c89b96887feb44d986fb"},"posted_at":"2026-06-29T21:33:22.623Z","created_at":"2026-06-29T21:33:22.623Z","updated_at":"2026-07-17T02:42:04.241Z","machine":{"shape":"article.machine/v1","slug":"ss-31-gut","kind":"article","read":{"human":"https://miscsubjects.com/a/ss-31-gut","json":"https://miscsubjects.com/api/articles/ss-31-gut","bundle":"https://miscsubjects.com/api/articles/ss-31-gut/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/ss-31-gut/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=ss-31-gut","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-gut\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-gut\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/ss-31-gut/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"ss-31-gut\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/ss-31-gut | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/ss-31-gut","json":"/api/articles/ss-31-gut","markdown":"/api/articles/ss-31-gut/bundle?format=markdown","skill":"/api/articles/ss-31-gut/skill","topology":"/api/articles/ss-31-gut/topology","versions":"/api/articles/ss-31-gut/revisions","invocations":"/api/articles/ss-31-gut/invocations"},"editorial_review":null,"editorial_audit":{"slug":"ss-31-gut","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"cb54f4766e31026da32daf881b3666965ee597d835c84d97a6dd20d6cdb696a8"}}}